Combined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors
Open Access
- 26 February 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 45 (3) , 746-754
Abstract
Immunotherapy is often effective only for small tumor burdens and, in many cases, is restricted to subcutaneous tumors. Here, we investigated the antitumor effects of combination therapy with GM-CSF and IL-12 on orthotopic liver tumors with intermediate or large tumor volumes, or on chemically-induced multifocal liver tumors in animals. Adenoviruses encoding GM-CSF or IL-12 were injected intratumorally to animals bearing transplanted tumors, or injected via intrahepatic artery in animals with primary multifocal liver tumors induced by diethylnitrosamine. Our results demonstrated that IL-12, but not GM-CSF, monotherapy displayed significant therapeutic effects, whereas combination therapy with both cytokines displayed synergistic antitumor effects not only on transplanted tumor models with intermediate or large tumor loads, but also on carcinogen-induced multifocal liver tumors. Effector cell analyses, revealed by in vivo cell subset depletion, flow cytometry analysis, and immunohistochemical staining of tumor infiltrates, indicated that NK cells were the prominent antitumor effectors for the IL-12–mediated antitumor activity, whereas CD8+ T cells, NKT cells, and macrophages were more important than NK cells in the combination therapy–mediated antitumor effects. Both IL-12 monotherapy and combination therapy could induce various types of effectors and high levels of IFN-γ; however, the latter induced much higher levels than the former, which may explain why combination therapy is superior to IL-12 monotherapy. Conclusion: Combination therapy with GM-CSF and IL-12 represents a promising immunotherapy strategy for treating orthotopic, widespread liver tumors. (Hepatology 2007;45:746–754.)Keywords
This publication has 25 references indexed in Scilit:
- A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillanceJournal of Experimental Medicine, 2005
- Functionally distinct NKT cell subsets and subtypesJournal of Experimental Medicine, 2005
- Differential antitumor immunity mediated by NKT cell subsets in vivoJournal of Experimental Medicine, 2005
- To be or not to be NKT: Natural killer T cells in the liverHepatology, 2004
- The Regulatory Role of Vα14 NKT Cells in Innate and Acquired Immune ResponseAnnual Review of Immunology, 2003
- Concurrent delivery of GM‐CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumorsThe Journal of Gene Medicine, 2003
- Construction of Single-Chain Interleukin-12 DNA Plasmid to Treat Airway Hyperresponsiveness in an Animal Model of AsthmaHuman Gene Therapy, 2001
- Combined IL-12 and GM-CSF gene therapy for murine hepatocellular carcinomaCancer Gene Therapy, 2001
- Regression of Established Mouse Leukemia by GM-CSF-Transduced Tumor Vaccine: Implications for Cytotoxic T Lymphocyte Responses and Tumor BurdensHuman Gene Therapy, 1997
- Evidence that granulocyte macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers.Journal of Clinical Investigation, 1993